Search

Your search keyword '"Pei, Lixia"' showing total 213 results
Start Over Author "Pei, Lixia" Search Limiters Full Text
213 results on '"Pei, Lixia"'

2. Teclistamab versus real-world physicians choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.

Author

Krishnan, Amrita, Nooka, Ajay, Chari, Ajai, Garfall, Alfred, Martin, Thomas, Nair, Sandhya, Lin, Xiwu, Qi, Keqin, Londhe, Anil, Pei, Lixia, Ammann, Eric, Kobos, Rachel, Smit, Jennifer, Parekh, Trilok, Marshall, Alexander, Slavcev, Mary, and Usmani, Saad

Subjects
B-cell maturation antigen, MajesTEC-1, bispecific antibody, comparative effectiveness, indirect treatment comparison, Humans, Multiple Myeloma, Treatment Outcome, Dexamethasone, Antineoplastic Agents, Physicians, Antineoplastic Combined Chemotherapy Protocols
Abstract

Aim: We compared the effectiveness of teclistamab versus real-world physicians choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC-1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were adjusted using inverse probability of treatment weighting. Overall survival, progression-free survival and time to next treatment were compared. Results: After inverse probability of treatment weighting, baseline characteristics were similar between cohorts (teclistamab, n = 165; RWPC, n = 364 [766 observations]). Teclistamab treated patients had numerically better overall survival (hazard ratio [HR]: 0.82 [95% CI: 0.59-1.14]; p = 0.233) and significantly greater progression-free survival (HR: 0.43 [0.33-0.56]; p

Published
2023

3. Teclistamab in Relapsed or Refractory Multiple Myeloma

Author

Moreau, Philippe, Garfall, Alfred L, van de Donk, Niels WCJ, Nahi, Hareth, San-Miguel, Jesús F, Oriol, Albert, Nooka, Ajay K, Martin, Thomas, Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Benboubker, Lotfi, Mateos, Maria-Victoria, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Sidana, Surbhi, Delforge, Michel, Pei, Lixia, Trancucci, Danielle, Verona, Raluca, Girgis, Suzette, Lin, Shun XW, Olyslager, Yunsi, Jaffe, Mindy, Uhlar, Clarissa, Stephenson, Tara, Van Rampelbergh, Rian, Banerjee, Arnob, Goldberg, Jenna D, Kobos, Rachel, Krishnan, Amrita, and Usmani, Saad Z

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Rare Diseases, Hematology, Immunotherapy, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Cancer, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, B-Cell Maturation Antigen, CD3 Complex, Humans, Injections, Subcutaneous, Multiple Myeloma, Neoplasm Recurrence, Local, Recurrence, T-Lymphocytes, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundTeclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma.MethodsIn this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better).ResultsAmong 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2).ConclusionsTeclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.).

Published
2022

10. A 6-lncRNA Signature to Improve Prognostic Prediction of Colon Cancer

Author

Wang Yuhang, Chen Lu, Pei Lixia, Chen Yufeng, Hu Yue, Hou Wenzhen, Song Yafang, Sun Mengzhu, and Sun Jianhua

Subjects
Medicine, Biology (General), QH301-705.5
Abstract

Background and Objective: Background and Objective: Colorectal cancer is one of the most common malignant tumors in the world. The prognosis of colorectal cancer is still considered as worse despite the rapid development of treatment methods in the recent years. Therefore, it is important to understand the pathogenesis and development for more accurate prognostic methods. The present study aimed to identify a long non‑coding (lnc) RNAs‑based signature for prognostic determination of colon cancer patients. Methods: Datasets from the GEO and TCGA databases were used, differential expression of lncRNA was analyzed, and a 6‑lncRNA signature was identified. KEGG and GO was used to enrich the signal pathway to determine the biological effects of these 6-lncRNA. Results: This study has designed a prognosis model containing “LINC01494”, “TRPM2-AS”, “ATP1A1-AS1”, “FRY-AS1”, “LINC01360”, and “RBFADN” based on data set of colorectal cancer patients available in the TCGA and GEO databases. The prognostic model of lncRNAs may predict the prognosis of patients with colorectal cancer. Conclusion: The present study identified a 6‑lncRNA signature that could predict the survival rate for colon cancer patients. Further studies may be carried out to strengthen the findings of the present study.

Published
2021
Full Text
View/download PDF

11. Forces Bless You: Mechanosensitive Piezo Channels in Gastrointestinal Physiology and Pathology.

Author

Guo, Jing, Li, Li, Chen, Feiyi, Fu, Minhan, Cheng, Cheng, Wang, Meizi, Hu, Jun, Pei, Lixia, and Sun, Jianhua

Subjects
INFLAMMATORY bowel diseases, CALCIUM channels, IRRITABLE colon, GASTROINTESTINAL diseases, MECHANORECEPTORS
Abstract

The gastrointestinal (GI) tract is an organ actively involved in mechanical processes, where it detects forces via a mechanosensation mechanism. Mechanosensation relies on specialized cells termed mechanoreceptors, which convert mechanical forces into electrochemical signals via mechanosensors. The mechanosensitive Piezo1 and Piezo2 are widely expressed in various mechanosensitive cells that respond to GI mechanical forces by altering transmembrane ionic currents, such as epithelial cells, enterochromaffin cells, and intrinsic and extrinsic enteric neurons. This review highlights recent research advances on mechanosensitive Piezo channels in GI physiology and pathology. Specifically, the latest insights on the role of Piezo channels in the intestinal barrier, GI motility, and intestinal mechanosensation are summarized. Additionally, an overview of Piezo channels in the pathogenesis of GI disorders, including irritable bowel syndrome, inflammatory bowel disease, and GI cancers, is provided. Overall, the presence of mechanosensitive Piezo channels offers a promising new perspective for the treatment of various GI disorders. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. P893: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS PHYSICIAN’S CHOICE THERAPY IN TRIPLE-CLASS EXPOSED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHED COHORT ANALYSIS

Author

Oriol, Albert, primary, Qi, Keqin, additional, Londhe, Anil, additional, Nair, Sandhya, additional, Lin, Xiwu, additional, Pei, Lixia, additional, Ammann, Eric, additional, Heuck, Christoph, additional, Renaud, Thomas, additional, Kane, Colleen, additional, Parekh, Trilok, additional, and Peterson, Steve, additional

Published
2023
Full Text
View/download PDF

15. Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma

Author

Moreau, Philippe, primary, van de Donk, Niels WCJ, additional, Nahi, Hareth, additional, Oriol, Albert, additional, Nooka, Ajay K, additional, Martin, Thomas, additional, Rosinol, Laura, additional, Karlin, Lionel, additional, Benboubker, Lotfi, additional, Mateos, Maria-Victoria, additional, Popat, Rakesh, additional, Martínez-López, Joaquín, additional, Sidana, Surbhi, additional, Delforge, Michel, additional, Pei, Lixia, additional, Trancucci, Danielle, additional, Olyslager, Yunsi, additional, Uhlar, Clarissa, additional, Stephenson, Tara, additional, Rampelbergh, Rian Van, additional, Banerjee, Arnob, additional, Kobos, Rachel, additional, and Usmani, Saad Z, additional

Published
2023
Full Text
View/download PDF

17. Prognostic value of positron emission tomography/computed tomography in transplanteligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study

Author

MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, MS Radiologie, Kraeber-Bodéré, Françoise, Zweegman, Sonja, Perrot, Aurore, Hulin, Cyrille, Caillot, Denis, Facon, Thierry, Leleu, Xavier, Belhadj, Karim, Itti, Emmanuel, Karlin, Lionel, Bailly, Clément, Levin, Mark-David, Minnema, Monique C, Jamet, Bastien, Bodet-Milin, Caroline, De Keizer, Bart, Béné, Marie C, Avet-Loiseau, Hervé, Sonneveld, Pieter, Pei, Lixia, Rigat, Fabio, De Boer, Carla, Vermeulen, Jessica, Kampfenkel, Tobias, Lambert, Jérôme, Moreau, Philippe, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, MS Radiologie, Kraeber-Bodéré, Françoise, Zweegman, Sonja, Perrot, Aurore, Hulin, Cyrille, Caillot, Denis, Facon, Thierry, Leleu, Xavier, Belhadj, Karim, Itti, Emmanuel, Karlin, Lionel, Bailly, Clément, Levin, Mark-David, Minnema, Monique C, Jamet, Bastien, Bodet-Milin, Caroline, De Keizer, Bart, Béné, Marie C, Avet-Loiseau, Hervé, Sonneveld, Pieter, Pei, Lixia, Rigat, Fabio, De Boer, Carla, Vermeulen, Jessica, Kampfenkel, Tobias, Lambert, Jérôme, and Moreau, Philippe

Published
2023

18. Electroacupuncture alleviates water avoidance stress-induced irritable bowel syndrome in mice by improving intestinal barrier functions and suppressing the expression of inflammatory cytokines

Author

SUN, Mengzhu, ZHANG, Yujie, SONG, Yafang, GUO, Jing, WANG, Yuhang, XIN, Chen, GU, Dongmei, SUN, Jianhua, and PEI, Lixia

Subjects
Original Articles
Abstract

OBJECTIVE: To evaluate the effects and related mechanisms of electroacupuncture (EA) on irritable bowel syndrome (IBS). METHODS: Male C57BL/6 mice were randomly allocated into normal, model, and EA groups. Experimental IBS mice models were established by exposure to water avoidance stress (WAS). Mice in the EA group were treated with EA at bilateral Tianshu (ST 25) and Zusanli (ST 36) for 7 consecutive days, 15 min each day. Abdominal withdrawal reflex (AWR) tests and intestinal motility tests were performed to evaluate visceral sensitivity and intestinal motility of mice. Expression levels of tight junction proteins (TJPs) and inflammatory cytokines in colon tissues were determined through immunofluorescence, real-time polymerase chain reactions (PCR) and Western blot assays. RESULTS: EA alleviated visceral hypersensitivity and intestinal hypermotility in WAS-induced IBS mice. Moreover, EA promoted the expression of zonula occludens (ZO)-1, claudin-1, and occludin while suppressing the expression of interleukin (IL)-8, interferon (IFN)-γ, and tumor necrosis factor (TNF)-αin water avoidance stress (WAS)-induced irritable bowel syndrome (IBS) mice. CONCLUSION: EA alleviated WAS-induced IBS in mice by promoting intestinal barrier functions and suppressing the expression of inflammatory cytokines.

Published
2023

19. Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma

Author

Miao, Xin, primary, Wu, Liviawati S., additional, Wang Lin, Shun Xin, additional, Xu, Yan, additional, Chen, Yang, additional, Iwaki, Yuki, additional, Kobos, Rachel, additional, Stephenson, Tara, additional, Kemmerer, Kristy, additional, Uhlar, Clarissa M., additional, Banerjee, Arnob, additional, Goldberg, Jenna D., additional, Trancucci, Danielle, additional, Verona, Raluca, additional, Pei, Lixia, additional, Su, Yaming, additional, Ouellet, Daniele, additional, Garfall, Alfred L., additional, Krishnan, Amrita Y., additional, Usmani, Saad, additional, Girgis, Suzette, additional, and Zhou, Honghui, additional

Published
2022
Full Text
View/download PDF

20. Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Author

Cortes-Selva, Diana, primary, Casneuf, Tineke, additional, Vishwamitra, Deeksha, additional, Stein, Sarah, additional, Perova, Tatiana, additional, Skerget, Sheri, additional, Ramos, Elena, additional, van Steenbergen, Laure, additional, De Maeyer, Dries, additional, Boominathan, Rengasamy, additional, Lau, Onsay, additional, Davis, Cuc, additional, Banerjee, Arnob, additional, Stephenson, Tara, additional, Uhlar, Clarissa M., additional, Kobos, Rachel, additional, Goldberg, Jenna D., additional, Pei, Lixia, additional, Trancucci, Danielle, additional, Girgis, Suzette, additional, Wang Lin, Shun Xin, additional, Wu, Liviawati S., additional, Moreau, Philippe, additional, Usmani, Saad, additional, Bahlis, Nizar Jacques, additional, Van De Donk, Niels WCJ, additional, and Verona, Raluca, additional

Published
2022
Full Text
View/download PDF

21. MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody

Author

Kumar, Shaji K, primary, Garfall, Alfred L., additional, Trudel, Suzanne, additional, Ocio, Enrique M., additional, Scott, Emma, additional, Huang, Lin, additional, Ma, Xuewen, additional, Olyslager, Yunsi, additional, Thakkar, Payal, additional, Pei, Lixia, additional, Heuck, Christoph, additional, and Terpos, Evangelos, additional

Published
2022
Full Text
View/download PDF

22. MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Author

Zamagni, Elena, primary, Boccadoro, Mario, additional, Spencer, Andrew, additional, Delforge, Michel, additional, Reece, Donna E., additional, Gyula Szabo, Agoston, additional, Einsele, Hermann, additional, Terpos, Evangelos, additional, Schjesvold, Fredrik, additional, Bila, Jelena, additional, Driessen, Christoph, additional, Beksac, Meral, additional, Cook, Gordon, additional, Rodriguez, Cesar, additional, Pei, Lixia, additional, Shi, Yingqi, additional, Sakabedoyan, Caline, additional, Jasielec, Jagaoda, additional, Amin, Himal, additional, Kobos, Rachel, additional, Sonneveld, Pieter, additional, and Van De Donk, Niels WCJ, additional

Published
2022
Full Text
View/download PDF

23. MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy

Author

Cohen, Yaël C., primary, Moreau, Philippe, additional, Tolbert, Jaszianne, additional, Qin, Xiang, additional, Ma, Xuewen, additional, Vieyra, Diego, additional, Langlois, Angelique, additional, Courtoux, Christelle, additional, Terry, William, additional, Pei, Lixia, additional, Heuck, Christoph, additional, and Voorhees, Peter, additional

Published
2022
Full Text
View/download PDF

24. Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study

Author

Kraeber-Bodéré, Françoise, primary, Zweegman, Sonja, additional, Perrot, Aurore, additional, Hulin, Cyrille, additional, Caillot, Denis, additional, Facon, Thierry, additional, Leleu, Xavier, additional, Belhadj, Karim, additional, Itti, Emmanuel, additional, Karlin, Lionel, additional, Bailly, Clément, additional, Levin, Mark-David, additional, Minnema, Monique C., additional, Jamet, Bastien, additional, Bodet-Milin, Caroline, additional, De Keizer, Bart, additional, Béné, Marie C., additional, Avet-Loiseau, Hervé, additional, Sonneveld, Pieter, additional, Pei, Lixia, additional, Rigat, Fabio, additional, De Boer, Carla, additional, Vermeulen, Jessica, additional, Kampfenkel, Tobias, additional, Lambert, Jérôme, additional, and Moreau, Philippe, additional

Published
2022
Full Text
View/download PDF

28. Electroacupuncture at Tianshu (ST25) and Zusanli (ST36) alleviates stress-induced irritable bowel syndrome in mice by modulating gut microbiota and corticotropin-releasing factor

Author

SUN, Mengzhu, ZHANG, Yujie, SONG, Yafang, GUO, Jing, ZHAO, Tingting, WANG, Yuhang, PEI, Lixia, and SUN, Jianhua

Subjects
Irritable Bowel Syndrome, Mice, Inbred C57BL, Mice, Electroacupuncture, Corticotropin-Releasing Hormone, RNA, Ribosomal, 16S, Animals, Dysbiosis, Acupuncture Points, Research Articles, Gastrointestinal Microbiome
Abstract

OBJECTIVE: To investigate whether electroacupuncture (EA) at bilateral Tianshu (ST25) and Zusanli (ST36) acupoints could alleviate stress-induced irritable bowel syndrome (IBS) and evaluate its effect on gut microbiota and corticotropin-releasing factor (CRF). METHODS: Thirty C57BL/6 mice were randomly divided into the normal, water avoidance stress (WAS), and WAS+EA groups (10 mice per group). An experimental model of IBS was established by exposing the animals to WAS. The mice were treated with EA at the bilateral Tianshu (ST25) and Zusanli (ST36) acupoints. The abdominal withdrawal reflex test was conducted to evaluate visceral sensitivity in IBS. Gut microbiota was analyzed using 16S rRNA sequencing and analysis. The expression of CRF was determined using immune-ofluorescence and quantitative real-time polymerase chain reaction. RESULTS: EA alleviated visceral hypersensitivity in a mouse model of WAS-induced IBS. It modulated the dysbiosis of gut microbiota induced by WAS. Moreover, it suppressed the WAS-induced overexpression of CRF in colon tissues. CONCLUSION: The findings of this study suggest that EA alleviated WAS-induced IBS via mechanisms possibly involving the modulation of the dysbiosis of gut microbiota and suppression of CRF expression.

Published
2022

29. A 6-lncRNA Signature to Improve Prognostic Prediction of Colon Cancer

Author

Hou Wenzhen, Pei Lixia, Sun Jianhua, Sun Mengzhu, Chen Yufeng, Hu Yue, Song Yafang, Chen Lu, and Wang Yuhang

Subjects
Oncology, medicine.medical_specialty, Colorectal cancer, business.industry, Internal medicine, medicine, Prognostic prediction, General Medicine, medicine.disease, business, Signature (logic)
Published
2021

30. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study

Author

Hulin, Cyrille, Offner, Fritz, Moreau, Philippe, Roussel, Murielle, Belhadj, Karim, Benboubker, Lotfi, Caillot, Denis, Facon, Thierry, Garderet, Laurent, Kuhnowski, Frédérique, Stoppa, Anne-Marie, Kolb, Brigitte, Tiab, Mourad, Jie, Kon-Siong, Westerman, Matthijs, Lambert, Jérôme, Pei, Lixia, Vanquickelberghe, Veronique, de Boer, Carla, Vermeulen, Jessica, Kampfenkel, Tobias, Sonneveld, Pieter, and van de Donk, Niels W.C.J.

Subjects
Letters to the Editor
Published
2021

31. Teclistamab in Relapsed or Refractory Multiple Myeloma.

Author

Karlin, Lionel, Karlin, Lionel, Benboubker, Lotfi, Mateos, Maria-Victoria, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Sidana, Surbhi, Delforge, Michel, Pei, Lixia, Trancucci, Danielle, Verona, Raluca, Girgis, Suzette, Lin, Shun, Olyslager, Yunsi, Jaffe, Mindy, Uhlar, Clarissa, Stephenson, Tara, Van Rampelbergh, Rian, Banerjee, Arnob, Goldberg, Jenna, Kobos, Rachel, Krishnan, Amrita, Usmani, Saad, Moreau, Philippe, Garfall, Alfred, van de Donk, Niels, Nahi, Hareth, San-Miguel, Jesús, Oriol, Albert, Nooka, Ajay, Martin, Thomas, Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Karlin, Lionel, Benboubker, Lotfi, Mateos, Maria-Victoria, Bahlis, Nizar, Popat, Rakesh, Besemer, Britta, Martínez-López, Joaquín, Sidana, Surbhi, Delforge, Michel, Pei, Lixia, Trancucci, Danielle, Verona, Raluca, Girgis, Suzette, Lin, Shun, Olyslager, Yunsi, Jaffe, Mindy, Uhlar, Clarissa, Stephenson, Tara, Van Rampelbergh, Rian, Banerjee, Arnob, Goldberg, Jenna, Kobos, Rachel, Krishnan, Amrita, Usmani, Saad, Moreau, Philippe, Garfall, Alfred, van de Donk, Niels, Nahi, Hareth, San-Miguel, Jesús, Oriol, Albert, Nooka, Ajay, Martin, Thomas, Rosinol, Laura, and Chari, Ajai

Abstract

BACKGROUND: Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better). RESULTS: Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2). CONCLUSIONS: Teclistamab resulted in a high rate of

Published
2022

32. Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Author

Popat, Rakesh, Saad Usmani, Garfall, Alfred, Donk, Niels, Nahi, Hareth, San-Miguel, Jesus F., Oriol, Albert, Nooka, Ajay, Martin, Thomas, Rosinol, Laura, Chari, Ajai, Karlin, Lionel, Benboubker, Lotfi, Mateos, Maria-Victoria, Bahlis, Nizar, Moreau, Philippe, Besemer, Britta, Martinez-Lopez, Joaquin, Sidana, Surbhi, Pei, Lixia, Trancucci, Danielle, Verona, Raluca, Girgis, Suzette, Olyslager, Yunsi, Jaffe, Mindy, Uhlar, Clarissa, Stephenson, Tara, Rampelbergh, Rian, Banerjee, Arnob, Goldberg, Jenna D., Kobos, Rachel, and Krishnan, Amrita

Published
2022

35. Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Author

Moreau, Philippe, primary, Usmani, Saad Z., additional, Garfall, Alfred L., additional, van de Donk, Niels W.C.J., additional, Nahi, Hareth, additional, San-Miguel, Jesus, additional, Oriol, Albert, additional, Nooka, Ajay K., additional, Martin, Thomas, additional, Rosinol, Laura, additional, Chari, Ajai, additional, Karlin, Lionel, additional, Benboubker, Lotfi, additional, Mateos, Maria-Victoria, additional, Bahlis, Nizar J., additional, Popat, Rakesh, additional, Besemer, Britta, additional, Martínez-López, Joaquín, additional, Sidana, Surbhi, additional, Pei, Lixia, additional, Trancucci, Danielle, additional, Verona, Raluca I., additional, Girgis, Suzette, additional, Olyslager, Yunsi, additional, Jaffe, Mindy, additional, Uhlar, Clarissa M., additional, Stephenson, Tara, additional, Van Rampelbergh, Rian, additional, Banerjee, Arnob, additional, Goldberg, Jenna D., additional, Kobos, Rachel, additional, and Krishnan, Amrita Y., additional

Published
2021
Full Text
View/download PDF

36. A Bibliometric Analysis of Research Trends of Acupuncture Therapy in the Treatment of Migraine from 2000 to 2020

Author

Zhao,Tingting, Guo,Jing, Song,Yafang, Chen,Hao, Sun,Mengzhu, Chen,Lu, Geng,Hao, Pei,Lixia, and Sun,Jianhua

Subjects
Journal of Pain Research
Abstract

Tingting Zhao,1,* Jing Guo,1,* Yafang Song,2 Hao Chen,2 Mengzhu Sun,1 Lu Chen,3 Hao Geng,3 Lixia Pei,3 Jianhua Sun3 1Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, People’s Republic of China; 2Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, People’s Republic of China; 3Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu Province, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jianhua Sun; Lixia PeiDepartment of Acupuncture Rehabilitation, The Affiliated Hospital of Nanjing University of Chinese Medicine, Hanzhong Road, Qinhuai District, Nanjing, Jiangsu Province, People’s Republic of ChinaEmail 377201634@qq.com; 11801758@qq.comBackground: Migraine is the second-leading cause of disability worldwide. It is often characterized by attacks of severe, mostly unilateral, pulsating headache associated with symptoms such as photophobia, phonophobia, nausea, vomiting, and cutaneous allodynia. Acupuncture therapy has been used worldwide for the treatment of migraine. However, no visual bibliometric analysis has been conducted on the effects of acupuncture on migraine over the past 20 years. Therefore, this study aimed to explore the current status and trends on the use of acupuncture in the treatment of migraine from 2000 to 2020.Purpose: The objective of this study is to identify the current status and emerging trends of the global use of acupuncture on migraine from 2000 to 2020 using CiteSpace and VOSviewer.Methods: Web of Science databases were searched for publications related to acupuncture therapy for treating migraine between 2000 and 2020. CiteSpace and VOSviewer were used to analyze the number of publications per year, countries, institutions, authors, journals, references, and keywords.Results: A total of 572 publications were included in the final analysis. The total number of publications has continued to increase with some fluctuations over the past 20 years. The most productive country and institution in this field were the USA, and Chengdu University of Traditional Chinese Medicine, respectively. The most active and cited authors were Liang FR and Linde K, respectively. Cephalalgia was the most productive, cited, and co-cited journal. The Linde K (2005) had the highest co-citation, citation number and centrality. The keywords “migraine” ranked first in frequency. The common type of migraine (tension-type headache), research method (randomized controlled trial, multicenter, double-blind), acupuncture’s role (prophylactic, quality of life, pain), and evaluation (meta-analysis, systematic review) were the hotspots and frontier trends of acupuncture therapy on migraine between 2000 and 2020.Conclusion: The present study examined the research-related trend in acupuncture therapy on migraine using bibliometric methods and identified the statement and research frontiers over the past two decades. This may help researchers to identify potential hotspots and new directions for future research in this field.Keywords: acupuncture, migraine, bibliometric analysis, CiteSpace, VOSviewer, network

Published
2021

46. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study

Author

Hulin, Cyrille, primary, Offner, Fritz, additional, Moreau, Philippe, additional, Roussel, Murielle, additional, Belhadj, Karim, additional, Benboubker, Lotfi, additional, Caillot, Denis, additional, Facon, Thierry, additional, Garderet, Laurent, additional, Kuhnowski, Frédérique, additional, Stoppa, Anne-Marie, additional, Kolb, Brigitte, additional, Tiab, Mourad, additional, Jie, Kon-Siong, additional, Westerman, Matthijs, additional, Lambert, Jérôme, additional, Pei, Lixia, additional, Vanquickelberghe, Veronique, additional, De Boer, Carla, additional, Vermeulen, Jessica, additional, Kampfenkel, Tobias, additional, Sonneveld, Pieter, additional, and Van de Donk, Niels W.C.J., additional

Published
2021
Full Text
View/download PDF

48. Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Author

Garfall, Alfred L., primary, Usmani, Saad Z., additional, Mateos, María-Victoria, additional, Nahi, Hareth, additional, van de Donk, Niels W.C.J., additional, San-Miguel, Jesus F., additional, Oriol Rocafiguera, Albert, additional, Rosinol, Laura, additional, Chari, Ajai, additional, Bhutani, Manisha, additional, Pei, Lixia, additional, Verona, Raluca, additional, Girgis, Suzette, additional, Stephenson, Tara, additional, Goldberg, Jenna D., additional, Banerjee, Arnob, additional, and Krishnan, Amrita, additional

Published
2020
Full Text
View/download PDF

50. Effect of Acupuncture in Patients With Irritable Bowel Syndrome: A Randomized Controlled Trial

Author

Pei, Lixia, primary, Geng, Hao, additional, Guo, Jing, additional, Yang, Guohui, additional, Wang, Lin, additional, Shen, Rongrong, additional, Xia, Shuyu, additional, Ding, Min, additional, Feng, Hua, additional, Lu, Jin, additional, Li, Jing, additional, Liu, Lian, additional, Shu, Yanye, additional, Fang, Xiangdong, additional, Wu, Xiaoliang, additional, Wang, Xiaoxiao, additional, Weng, Shengjie, additional, Ju, Lu, additional, Chen, Xiao, additional, Shen, Hong, additional, and Sun, Jianhua, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results